Global
Fc Protein and Glycoengineered Antibodies Market Drivers
Key players in the market are
focusing on research and development activities and receiving approvals from
regulatory bodies, which are expected to boost the global Fc protein and
glycoengineered antibodies market growth over the forecast period.
For instance, in 2016, Genentech
Inc. received approval from the U.S. Food and drug Administration (U.S. FDA)
for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial
carcinoma. In March 2019, Tecentriq received its second approval from the U.S.
FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG
Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of
multiple sclerosis. It is currently in third phase of its clinical trial.
Factors such as increasing product approvals and robust pipeline are expected
to drive the global fc protein and glycoengineered antibodies market
growth.
Increasing prevalence of diseases
such as cancer is expected to propel the global Fc protein and glycoengineered
antibodies market growth. According to the World Health Organization (WHO),
cancer is considered as the second most leading cause of death worldwide, and,
in 2018, around 9.6 million people died worldwide due to cancer. Hence,
glycoengineered antibodies can be developed for the treatment of cancer and
thus, this factor is expected to drive growth of the global fc protein and
glycoengineered antibodies market over the forecast period.
Global Fc Protein and Glycoengineered Antibodies Market
Restraints
High cost of drugs is expected to
hinder the global Fc
protein and glycoengineered antibodies market growth. Manufacturers are
focused on offering a highly effective drug, thus investing more into research
and development activities. This increases the final cost price of the product.
According to Pharmacy and Healthcare Communication, LLC, Gazyva costs around
US$ 41,300 for six months treatment of cancer. Hence, this factor is expected
to restrain growth of the global fc protein and glycoengineered antibodies
market.
Global Fc Protein and Glycoengineered Antibodies Market
Regional Analysis
North America region is expected to
dominate in the global fc protein and glycoengineered antibodies market due to
factors such as product launches, presence of leading manufacturers (such as F.
Hoffmann La-Roche Ltd.), and active research and development in the field.
Drugs such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab
(Tecentriq), and Durvalumab (Imfinzi) have been approved in the U.S. in 2013,
2018, 2016, and 2017 respectively.
Comments
Post a Comment